Tri-Med, Trenbolone Mix, 180 mg/ml, 10 ml

Tri-Med 180 mg/ml by Bioniche Pharma is an advanced multi-ester injectable solution combining fast-acting (acetate), intermediate (hexahydrobenzylcarbonate), and extended-release (enanthate) esters of Trenbolone. Designed by Bioniche Pharma to ensure an immediate onset alongside sustained blood plasma hormone levels, Bioniche Pharma Tri-Med stimulates cellular protein metabolism, drives nitrogen retention, prevents muscle degradation, and accelerates structural recovery when paired with appropriate nutritional support.

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

The specialized tri-ester blend of Bioniche Pharma Tri-Med combines complementary pharmacokinetic rates: Trenbolone Acetate provides a quick initial release, while Trenbolone Hexahydrobenzylcarbonate and Trenbolone Enanthate release gradually to preserve steady active levels. Upon binding to intracellular androgen receptors, Tri-Med by Bioniche Pharma enhances local IGF-1 synthesis, boosts protein translation, and improves cellular nitrogen uptake. As a non-aromatizing compound, Bioniche Pharma Tri-Med exerts strong anabolic effects without direct conversion to estrogen.

INDICATIONS & CLINICAL USE

• Targeted anabolic therapy to optimize systemic nitrogen balance, accelerate protein synthesis, and support tissue recovery using Bioniche Pharma Tri-Med.
• Clinical management of muscle wasting conditions and support of lean body mass retention in compromised individuals under qualified medical supervision.

CONTRAINDICATIONS

• Male individuals with diagnosed, suspected, or previously treated prostate carcinoma or breast cancer.
• Female patients presenting with breast carcinoma accompanied by hypercalcemia.
• Pregnant or nursing women due to severe risks of fetal virilization, structural developmental abnormalities, and profound endocrine toxicity. Women must strictly avoid Bioniche Pharma Tri-Med.
• Patients presenting with severe cardiovascular insufficiency, advanced hepatic dysfunction, or major renal impairment.
• Documented allergy or hypersensitivity to any of the Trenbolone esters, carrier media, or excipients contained in Tri-Med by Bioniche Pharma.

ADVERSE REACTIONS & SPECIAL PRECAUTIONS

• Dermatological & Androgenic: Manifestation of severe acne (frequently occurring across the face, shoulders, back, and upper chest during treatment start), heightened sebum production, and accelerated male pattern baldness (androgenetic alopecia).
• Behavioral & CNS: Dose-dependent changes in mood, increased irritability, heightened aggression, and sleep disturbances linked to Bioniche Pharma Tri-Med administration.
• Systemic & Organ Monitoring: Periodic clinical evaluation of renal values, liver enzyme activity, blood pressure, and serum lipid profiles is required during therapy with Tri-Med by Bioniche Pharma.
• Endocrine Suppression: Pronounced suppression of the endogenous Hypothalamic-Pituitary-Testicular Axis (HPTA), leading to transient secondary hypogonadism and testicular atrophy.

DOSAGE & ADMINISTRATION

Tri-Med by Bioniche Pharma is intended strictly for deep intramuscular administration. Due to the combination of rapid and slow-acting esters, administration scheduling should remain consistent to prevent hormonal fluctuations:

• Prescribed Dosage: Standard administration protocols typically call for 180 mg (1 ml) of Bioniche Pharma Tri-Med injected intramuscularly every second day, or as adjusted by a supervising physician.
• Restricted Populations: Strictly contraindicated for female patients, children, and adolescents.

STORAGE & HANDLING

Keep Bioniche Pharma Tri-Med in a cool, dry area shielded from direct light exposure and high heat. Do not refrigerate or freeze. Store securely out of the reach and sight of children.